ACR Convergence Replay 2024 Controversies in Treating ANCA-Associated Vasculitis
$12900
REPLAYVAS2024
Vasculitides
Thursday, May 8, 2025, 1:00 AM
Sunday, May 7, 2028, 11:55 PM
CME
Practice Administrators, Primary Care Providers, Researchers, Rheumatologists
1.25

Activity Information

This session in the ACR Convergence 2024 Replay series is a recorded webinar that took place on April 15, 2025.  The series features popular scientific sessions followed by a Q&A with the faculty.

This session is about the latest advancements and challenges in the management of ANCA-associated vasculitis (AAV). Although treatment guidelines have become available, many questions persist about their specific application to different clinical scenarios and the patient population with ANCA-associated vasculitis (AAV).


Target Audience

Rheumatologists, primary care providers, practice administrators, and healthcare providers who care for patients with rheumatic diseases, and those interested or engaged in rheumatology research.


Learning Objectives

Upon completion of this activity, participants should be able to do the following:

  • Review general and specific applications of the American College of Rheumatology/Vasculitis Foundation treatment guidelines for GPA and MPA
  • Discuss recent data regarding use of low versus standard dose glucocorticoids in AAV
  • Discuss and review applications for avacopan in AAV
  • Discuss and review current indications for plasmapheresis in AAV


CE and MOC Information

CME

Accreditation Statement

The American College of Rheumatology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


Designation Statement

The American College of Rheumatology designates this Enduring Activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME credit must be claimed by May 7, 2028, at 11:59 PM ET.


Financial Relationship Disclosures

ACR Disclosure Statement

It is the policy of the American College of Rheumatology (ACR) to ensure that Continuing Medical Education (CME) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners' and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at accme.org.

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CME activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CME activity.

Nature of Financial Relationships

All individuals that participate in an ACR-sponsored activity and are able to change content or influence the content of the activity must disclose to the planning committee and audience all financial or other relationships with ineligible companies including, but not limited to:

  1. Advisor or review panel member
  2. Consultant
  3. Employee
  4. Officer or Board Member
  5. Grant/research support
  6. Speaker/honoraria includes speaker’s bureau, symposia, and expert witness
  7. Independent contractor
  8. Executive role and/or ownership interest
  9. Royalties and/or patent beneficiary
  10. Intellectual property/patents
  11. Stock options or bond holdings in a for-profit corporation or self-directed pension plan
  12. Private investigator
  13. Expert witness
  14. Equity interest
  15. Other: specify details

None: Has no relevant financial relationship(s) with ineligible companies to disclose.

All participants that created and/or were able to influence the content and delivery of this activity reported the following disclosures. All of the relevant financial relationships listed have been mitigated. ACR Convergence 2024 Replay Controversies in the Treatment of ANCA-Associated Vasculitis Financial Relationship Disclosures 

Acknowledgement of Commercial Support

No commercial support was provided for this activity.

Educational Activity Policies

See ACR educational activity policies, including the online enduring activity refund policy.

ACR Convergence Replay 2024 Controversies in Treating ANCA-Associated Vasculitis

Hear advancements and challenges in the management of ANCA-associated vasculitis (AAV) including how to apply treatment guidelines to different clinical scenarios.